HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
HPV (Human papillomavirus) affects 600,000 people worldwide each year. Almost all cervical cancers are associated with a past HPV infection. In particular, the positivity to the high-risk type HPV16 is detected in most of the invasive cervical cancers. FDA has approved prophylactic vaccines that pro...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213285/full |
| _version_ | 1827903239964590080 |
|---|---|
| author | Kun Zhou Olga Yuzhakov Nouredine Behloul Dehua Wang Lakshmi Bhagat Dafeng Chu Xinyue Zhang Xinwei Cheng Lusheng Fan Xinyu Huang Teodelinda Mirabella |
| author_facet | Kun Zhou Olga Yuzhakov Nouredine Behloul Dehua Wang Lakshmi Bhagat Dafeng Chu Xinyue Zhang Xinwei Cheng Lusheng Fan Xinyu Huang Teodelinda Mirabella |
| author_sort | Kun Zhou |
| collection | DOAJ |
| description | HPV (Human papillomavirus) affects 600,000 people worldwide each year. Almost all cervical cancers are associated with a past HPV infection. In particular, the positivity to the high-risk type HPV16 is detected in most of the invasive cervical cancers. FDA has approved prophylactic vaccines that protect against new HPV16 infections, but do not induce immunity in those patients with established infections or neoplasms. To date, no therapeutic vaccine targeting HPV16-associated lesions has been authorized. We have developed an mRNA-based vaccine against the HPV16 late oncoproteins E6 and E7, which are abundantly and exclusively expressed in high-grade squamous intraepithelial lesions (HSILs), a stage of the cervical disease that precedes the progression to carcinoma. Our in vitro and in vivo studies demonstrated that the translated mRNA is functional and elicits an antigen-specific adaptive immune response. Upon immunization with the vaccine, mice with HPV16+ lesions exhibited tumor growth inhibition, extension of lifespan, and development of a protective immune memory. In light of these results and the remarkable clinical success of mRNA vaccines against SARS-CoV2, we believe that our mRNA-based therapeutic vaccine has the potential to offer a non-invasive treatment alternative to the current standard of care for HPV16+ HSILs. |
| first_indexed | 2024-03-13T00:10:03Z |
| format | Article |
| id | doaj.art-cfa39a6059cc46c39cd83382ad24bdc2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T00:10:03Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-cfa39a6059cc46c39cd83382ad24bdc22023-07-12T14:32:38ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.12132851213285HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesionsKun Zhou0Olga Yuzhakov1Nouredine Behloul2Dehua Wang3Lakshmi Bhagat4Dafeng Chu5Xinyue Zhang6Xinwei Cheng7Lusheng Fan8Xinyu Huang9Teodelinda Mirabella10R&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, Nanjing GeneLeap Biotechnology, Nanjing, ChinaR&D Department, Nanjing GeneLeap Biotechnology, Nanjing, ChinaR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, Nanjing GeneLeap Biotechnology, Nanjing, ChinaR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesR&D Department, GeneLeap Biotechnology, Woburn, MA, United StatesHPV (Human papillomavirus) affects 600,000 people worldwide each year. Almost all cervical cancers are associated with a past HPV infection. In particular, the positivity to the high-risk type HPV16 is detected in most of the invasive cervical cancers. FDA has approved prophylactic vaccines that protect against new HPV16 infections, but do not induce immunity in those patients with established infections or neoplasms. To date, no therapeutic vaccine targeting HPV16-associated lesions has been authorized. We have developed an mRNA-based vaccine against the HPV16 late oncoproteins E6 and E7, which are abundantly and exclusively expressed in high-grade squamous intraepithelial lesions (HSILs), a stage of the cervical disease that precedes the progression to carcinoma. Our in vitro and in vivo studies demonstrated that the translated mRNA is functional and elicits an antigen-specific adaptive immune response. Upon immunization with the vaccine, mice with HPV16+ lesions exhibited tumor growth inhibition, extension of lifespan, and development of a protective immune memory. In light of these results and the remarkable clinical success of mRNA vaccines against SARS-CoV2, we believe that our mRNA-based therapeutic vaccine has the potential to offer a non-invasive treatment alternative to the current standard of care for HPV16+ HSILs.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213285/fullmRNAlipid nanoparticlesHPVtherapeutic vaccinetumors |
| spellingShingle | Kun Zhou Olga Yuzhakov Nouredine Behloul Dehua Wang Lakshmi Bhagat Dafeng Chu Xinyue Zhang Xinwei Cheng Lusheng Fan Xinyu Huang Teodelinda Mirabella HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions Frontiers in Immunology mRNA lipid nanoparticles HPV therapeutic vaccine tumors |
| title | HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions |
| title_full | HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions |
| title_fullStr | HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions |
| title_full_unstemmed | HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions |
| title_short | HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions |
| title_sort | hpv16 e6 e7 based mrna vaccine is therapeutic in mice bearing aggressive hpv positive lesions |
| topic | mRNA lipid nanoparticles HPV therapeutic vaccine tumors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213285/full |
| work_keys_str_mv | AT kunzhou hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT olgayuzhakov hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT nouredinebehloul hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT dehuawang hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT lakshmibhagat hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT dafengchu hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT xinyuezhang hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT xinweicheng hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT lushengfan hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT xinyuhuang hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions AT teodelindamirabella hpv16e6e7basedmrnavaccineistherapeuticinmicebearingaggressivehpvpositivelesions |